Drosperin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Drosperin

Property Description
Active ingredient Drospirenone and Ethinyl Estradiol
Form Oral tablet
Pharmacological class Hormonal contraception (Progestin and Estrogen combination)
General purpose Pregnancy prevention
Origin Synthetic hormones

What Type of Medicine is Drosperin? (Identity and Classification)

Drosperin is a prescription-only medicine defined as a combination drug that functions as a highly effective form of Hormonal contraception. It belongs to the high-level pharmacological class of Sex hormones and modulators of the genital system and is provided in the physical form of an oral tablet for systemic administration. The combination of Drospirenone and Ethinyl Estradiol is a clinically recognized form of oral contraceptive utilized for its ability to regulate the menstrual cycle and prevent pregnancy. This identity establishes Drosperin as a first-line therapy option for women of reproductive age seeking reliable, non-barrier methods of fertility control. Other common brand names sharing this exact active ingredient combination include Yaz, Yasmin, and Ocella, all serving the same general purpose.

Composition and Unique Hormonal Components

Drosperin is a composite medication containing two primary synthetic hormones: Drospirenone and Ethinyl Estradiol. This dual composition utilizes a synthetic Progestin component (Drospirenone) and a synthetic Estrogen component (Ethinyl Estradiol), which are engineered to work in concert. The Drospirenone component provides significant differentiation: it is chemically unique among progestins due to its distinct antimineralocorticoid activity, a property related to aldosterone antagonism. This structural feature provides Drospirenone with differentiating pharmacological effects compared to other progestins. This specific hormonal combination and its unique properties in the oral tablet format define the medicine’s comprehensive profile.

The Primary Benefit of This Combination Drug

The essential benefit of Drosperin is to provide reliable oral contraception through the controlled, cyclical use of its two active ingredients, leading to robust pregnancy prevention. The combined presence of Ethinyl Estradiol and Drospirenone ensures concurrent protective effects, including the suppression of the natural signals that initiate the release of an egg, the alteration of the cervical mucus to create a physical barrier, and the modification of the endometrial lining. This coordinated, multi-mechanism action of the combination drug ensures its status as an established and highly effective tool for fertility management.

What side effects are possible with Drosperin?

Possible Side Effects and Safety Information

The official safety profile for Drospirenone and Ethinyl Estradiol (Drosperin) is structured by government regulators to detail known adverse reactions and high-level safety constraints. The information is grouped by frequency of occurrence and the body system affected, reflecting how regulatory documents communicate potential risks.

Common and Expected Adverse Reactions

Adverse reactions classified as very common (ge 1/10) or common (ge 1/100 to < 1/10) in official labeling include headache, nausea, breast pain/discomfort, menstrual irregularities (such as spotting or unscheduled bleeding), migraine, and mood changes (including depression or emotional lability).

Serious Adverse Reactions and Key Constraints

The most serious, though rare, safety concern documented is the risk of thromboembolic events, which includes Venous Thromboembolism (VTE) (like deep vein thrombosis or pulmonary embolism) and Arterial Thromboembolism (ATE) (like stroke or heart attack). Regulatory documents note that the risk of these events may be highest during the first year of use.

Due to the unique antimineralocorticoid activity of Drospirenone, there is a documented potential for hyperkalemia (elevated serum potassium). This constraint leads to specific contraindications, as the medicine should not be used in individuals with conditions that predispose to hyperkalemia, such as renal impairment, hepatic impairment, or adrenal insufficiency.

Population and Duration-Related Safety

Official safety information specifies that the risk of serious cardiovascular events is particularly high for smokers over age 35. Additionally, unscheduled bleeding and spotting are typically more common during the first three months of treatment. These constraints define the medicine's safety limits within specific patient groups and duration of use.

Overdose and Emergency Response

Overdose and When to Seek Help

Overexposure to Drospirenone and Ethinyl Estradiol (Drosperin) is characterized by officially documented manifestations and the potential for severe physiological consequences. Documented clinical presentations following an overdose may include nausea, vomiting, and withdrawal bleeding (or slight vaginal bleeding) in females. A specific note in regulatory documentation states that withdrawal bleeding may occur in girls before their menarche following accidental ingestion.

Immediate Medical Attention Required

In the event of a suspected overdose, immediate medical attention must be sought. This mandatory action is required because the drospirenone component carries a potential risk for severe, life-threatening outcomes, specifically hyperkalemia (elevated serum potassium concentration) and metabolic acidosis.

Treatment for overexposure is symptomatic and supportive. Regulatory guidelines require hospital monitoring, including the assessment of serum potassium and serum sodium concentrations and observation for evidence of metabolic acidosis. This specialized monitoring is necessary as no specific antidote is known for overdose with this combination product, making supportive care the established regulatory management approach.

Therapeutic Uses of Drosperin

Quick Facts about Drosperin

  • Therapeutic Domain: Contraception, Moderate Acne, PMDD.
  • Primary Use: Supports the prevention of pregnancy.
  • Secondary Use: Indicated for the management of moderate acne vulgaris.
  • Symptom Relief: Assists in addressing symptoms of Premenstrual Dysphoric Disorder (PMDD).

What Drosperin Treats: Main Uses and Benefits

Drosperin, a combined hormonal product, is utilized to provide contraception (to assist in preventing pregnancy) for women of reproductive potential. The medication is an established option within the domain of oral contraceptives.

In addition to its primary therapeutic domain, this formulation is indicated for the management of moderate acne vulgaris in females who have achieved menarche and who have also selected an oral contraceptive for birth control. It is also indicated for the treatment of symptoms associated with Premenstrual Dysphoric Disorder (PMDD) in women who choose an oral contraceptive for contraception.

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Drosperin (Drospirenone and Ethinyl Estradiol) is permitted for use by females of reproductive potential for pregnancy prevention, and for the management of moderate acne vulgaris in women at least 14 years old who have achieved menarche. It is not indicated for use before menstruation has started or in women after menopause.

The medicine is absolutely contraindicated in women who present with certain risk factors or pre-existing conditions, as defined in regulatory labeling:

  • Thrombotic Risk: Females over 35 years of age who smoke, or those with a history of venous or arterial thrombotic diseases (e.g., DVT, pulmonary embolism, stroke), or known thrombophilias.
  • Organ Function: Patients with renal impairment, adrenal insufficiency, or active liver disease/liver tumors.
  • Other Contraindications: Use is prohibited in pregnancy, in patients with hormone-sensitive cancers (e.g., breast cancer), undiagnosed abnormal uterine bleeding, or uncontrolled hypertension.

Use requires specific restriction in the following contexts: the medicine must be stopped at least four weeks before major surgery, and its use is not recommended during breastfeeding. Regular serum potassium monitoring is specified for patients taking other medications that may increase potassium levels.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Drosperin (Drospirenone and Ethinyl Estradiol) based on documented effects on drug metabolism and pharmacodynamic reinforcement. Co-administration with certain agents may alter drug exposure or pose specific risks.


Documented Interaction Categories

Category Interacting Agents / Official Outcome
Contraindicated Combinations Hepatitis C drug combinations containing ombitasvir, paritaprevir/ritonavir, with or without dasabuvir, are prohibited due to the risk of ALT enzyme elevations. Oral Tranexamic Acid is contraindicated due to documented pharmacodynamic synergism increasing thrombotic risk.
Pharmacokinetic Interactions Strong CYP3A4 inhibitors (e.g., ketoconazole) increase the plasma concentration of Drospirenone. Conversely, enzyme inducers (e.g., certain herbal products) may decrease component exposure, leading to reduced contraceptive effectiveness.
Pharmacodynamic Interactions Due to Drospirenone's anti-mineralocorticoid activity, co-administration with potassium-sparing diuretics, ACE inhibitors, ARBs, or NSAIDs potentiates the risk of hyperkalemia.

Population-Specific Constraint: The regulatory label notes that monitoring of serum potassium is required during the first treatment cycle for women taking long-term medications that may increase serum potassium or those on a strong CYP3A4 inhibitor.

Mechanism of Action

Drospirenone, a synthetic progestin, acts through multiple steroid hormone receptor targets. Its primary action is as an agonist at the progesterone receptor (PR), located within the nuclei of target cells in tissues such as the pituitary, ovaries, and uterus.

Binding to the PR forms a hormone-receptor complex that translocates to the nucleus and modulates gene transcription. In the pituitary, this action modifies the pulsatile secretion of gonadotropins, specifically suppressing the surge of Luteinizing Hormone (LH). The intracellular consequence is the interruption of the hypothalamic-pituitary-ovarian axis signaling, which physiologically prevents follicular maturation and the release of an ovum from the ovary.

Additionally, drospirenone functions as a non-selective antagonist at the mineralocorticoid receptor (MR). By blocking aldosterone from binding to the MR in the renal tubules, it inhibits sodium and water reabsorption and prevents potassium excretion, leading to a downstream natriuretic and potassium-sparing physiological consequence. Drospirenone also exhibits antagonistic activity at the androgen receptor (AR), blocking the effects of endogenous androgens.

Dosage and Administration Information

Administration Scope

Feature Description
Route of administration Oral (swallowed whole).
Dosing schedule One tablet daily (PO qDay) according to a 28-day cycle. Regimens include 24 consecutive days of active tablets followed by 4 inert tablets, or 21 active tablets followed by 7 inert tablets.
Timing in relation to meals May be taken with or without food. It must be taken at the same time every day, preferably in the evening.
Age-group administration rules Use is established for females who have achieved menarche. Use is contraindicated in patients with severe renal impairment or hepatic disease.
Missed-dose rules Specific protocols exist for missed active tablets; these procedures require that a non-hormonal backup contraceptive method be used for seven consecutive days following the omission of multiple active doses.
Special procedural conditions The tablet must be taken in the order directed on the blister pack, and a new 28-day pack must be started immediately following the completion of the prior pack.

Resulting Procedural Structure

Official step sequence:

  • Daily Ingestion: Take one tablet daily at the same time every day.
  • Follow Order: Ingest the tablets strictly in the order directed by the package to ensure the correct hormone sequence.
  • Continuous Cycle: Start the next 28-day pack immediately after finishing the last tablet (inert/placebo) of the current pack.

Connection to the overall use protocol: The official instructions mandate a rigid, cyclic administration pattern using a fixed oral dose taken once daily. This protocol defines the precise sequence of active and inert tablets over 28 continuous days and outlines procedural steps for managing deviations, such as following the missed dose instructions or accounting for severe gastrointestinal upset.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Design and Characteristics

Research protocols often include a discussion of the selective enzyme inhibition observed in laboratory studies. Studies investigated the compound's characteristics, including its selective enzyme inhibition.


Phase III Trial Findings

Studies evaluated this combination in populations with mild to moderate disease. Trial protocols focused on two primary endpoints: changes in motor function and time to symptom changes. Research explored whether there is an effect on motor function and time to symptom changes in patients enrolled in the trials.

  • Symptom Management: Research protocols examined the measurements of frequency and severity of episodes, and whether these measurements showed changes in symptoms. The study design followed participants for six months.
  • Combination vs. Monotherapy: Trials compared outcomes of this combination therapy versus monotherapy in relation to symptom control measurements.

Research Periods and Observations

Studies included research periods that involved extended treatment. This research involved observations over time, including data on sustained measurements and potential side effects.

  • Disease Progression: Research protocols included investigation into disease progression measurements over a two-year period in a subset of participants.
  • Measurements in Research: Research protocols involved the regular monitoring of liver enzyme measurements; the presence of a history of hepatic issues was a factor in some research designs.

Limitations and Future Direction

Evidence remains limited on the use of this combination in pediatric populations. Research findings were mixed in subjects with severe, end-stage presentations of the condition. Research indicates it is not yet clear whether the observed measurements extend to patients taking three or more concomitant medications. Further research is planned to explore these populations and potential drug-drug interactions.

Frequently Asked Questions (FAQ)

Common questions about Drosperin (FAQ)

Q: How is Drosperin different from other similar medicines?

Official product information describes the active ingredient Drospirenone as unique among progestins because it has two specific effects. It exhibits antimineralocorticoid activity, which relates to blocking the action of aldosterone, and also has anti-androgen activity. These distinct pharmacological properties differentiate it from other synthetic hormones in similar medicines.

Q: Do the side effects of Drosperin lessen over time?

Regulatory documents indicate that irregular bleeding or spotting is a common side effect, especially during the first few months of treatment. This symptom is typically more common during the first three cycles and is generally observed to lessen over time as the body adjusts to the medication.

Q: Does Drosperin interact with common herbal supplements or vitamins?

Official regulatory documents advise that certain herbal products can act as enzyme inducers, which means they can speed up the way the body breaks down the medicine. This process can potentially decrease the amount of the active ingredients in the body, which may reduce its intended effectiveness.

Q: Can Drosperin be taken with over-the-counter pain relievers like ibuprofen?

Regulatory information notes that because Drosperin contains Drospirenone (which has anti-mineralocorticoid activity), taking it with NSAIDs like ibuprofen may increase the risk of hyperkalemia (elevated serum potassium levels). For patients with certain pre-existing conditions, official information advises that monitoring of potassium levels may be necessary for patients considered high-risk.

Q: How is Drosperin typically broken down and eliminated from the body?

According to official product information, the active ingredient Drospirenone is extensively metabolized, meaning it is broken down through a process involving certain liver enzymes. The resulting substances, or metabolites, are then primarily eliminated from the body through both urine and feces.

Q: Is there a generic version of Drosperin available in most countries?

Drosperin is the brand name for a combination of two established active ingredients: Drospirenone and Ethinyl Estradiol. This combination is widely available, and official drug sources reference several generic and authorized brand-name equivalents that contain the same active ingredients.

Q: Does Drosperin have any known effect on fertility or conception?

The medicine’s primary mechanism is to provide reliable pregnancy prevention by stopping ovulation and making changes within the reproductive system. The time it may take for a person to return to their baseline ability to conceive after discontinuing the medicine is not consistently detailed in patient-facing summaries.

Q: How long can a person safely stay on Drosperin?

The official label does not specify a maximum duration of use. However, studies have evaluated the use of the active combination in various regimens for up to 2 years in certain populations, noting that the medicine was generally tolerated over that period.

Q: Is feeling tired or fatigued a common side effect of Drosperin?

Regulatory documents and study data indicate that fatigue (feeling tired or a lack of energy) has been reported as an adverse reaction. Some official sources list this symptom as a common side effect noted during clinical trials.

Q: Is it true Drosperin can cause changes in weight?

Changes in weight have been noted in the official safety profile for the medicine. Weight gain has been reported as a potential side effect in clinical trials, and some reports also include weight changes (gain or loss) in less common categories.

Q: Are there any specific foods that interact with Drosperin?

Official regulatory documents state that consuming grapefruit or grapefruit juice may need to be avoided. This is because these products may inhibit the metabolism of the active ingredient Drospirenone, which could potentially lead to higher-than-expected levels of the drug in the bloodstream.

Q: What are the general risks of drinking alcohol while taking Drosperin?

Official interaction profiles indicate a minor interaction between the Ethinyl Estradiol component of the medicine and alcohol. This interaction could potentially increase the severity of certain side effects associated with the Ethinyl Estradiol component.

Q: Can Drosperin be used by men for any approved indications?

According to regulatory labeling, Drosperin is indicated for use only in females of reproductive potential. The approved uses are specifically for pregnancy prevention, treating the symptoms of PMDD, and managing moderate acne in women who choose an oral contraceptive.

Q: How quickly can I expect to feel the primary effects of Drosperin?

The body needs time to build up the hormone levels required for effect. Steady-state concentrations of the active ingredient are observed after about 8 days of daily dosing. Contraceptive effectiveness is achieved after the first 7 consecutive days of product administration.

Q: Why does Drosperin sometimes carry a 'black box' warning in official documents?

The official label includes a Boxed Warning because of a serious, documented risk. This warning highlights that cigarette smoking significantly increases the chance of serious cardiovascular events (such as blood clots, stroke, or heart attack), especially for women over 35 years old who take the medicine.

Q: Does Drosperin interact with common antibiotics?

Regulatory documents do not specifically list all common antibiotics as a direct interaction. However, they advise that if any co-administered medicine causes vomiting or severe diarrhea, the absorption of Drosperin may be decreased. In such cases, a non-hormonal back-up method may be advised for seven days.

Q: What is the half-life of Drosperin in the average adult?

The half-life describes the time it takes for the concentration of a substance in the body to be reduced by half. For the Drospirenone component of the medicine, the terminal half-life is approximately 30 hours after multiple dose regimens.

Q: Are there any known symptoms related to taking too much Drosperin?

According to official safety information, symptoms of overdose that have been reported in clinical experience include nausea and, in females, vaginal bleeding.

Q: Can Drosperin affect cholesterol or blood sugar levels?

Regulatory documents mention the potential for carbohydrate and lipid metabolic effects while taking the medicine. For this reason, official information advises that monitoring may be necessary for women with prediabetes or diabetes.

Q: Does Drosperin contain common allergens like lactose, gluten, or soy?

The inactive components of the tablet often include common non-medicinal ingredients. Official documents for brand and generic equivalents often list ingredients such as lactose monohydrate and corn starch.

Q: What happens when I stop taking Drosperin?

Most women who stop taking the active tablets will experience withdrawal bleeding similar to a menstrual period shortly afterward. If the medicine was being used to manage PMDD, it may take several cycles for the symptoms of the condition to return to their previous state.

Q: Is there a known interaction between Drosperin and grapefruit juice?

Yes, official interaction information notes that consuming grapefruit or grapefruit juice may increase the plasma concentrations of the active ingredient Drospirenone. This effect is thought to occur because the fruit inhibits the enzyme that helps the body metabolize the drug.

How should Drosperin be stored and disposed of?

Storage and Disposal Instructions

The official labeling mandates that Drospirenone and Ethinyl Estradiol tablets must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F), with temporary excursions permitted outside this range. The product must be protected from light, heat, and excess moisture and should be kept in its original, tightly closed container.

Required Conditions

Category Requirement
Temperature Controlled Room Temp (20 C–25 C)
Protection Keep away from light, heat, and moisture
Access Store out of the reach of children

Regarding disposal, unused or expired medication must be handled according to local regulations. Official guidelines state that the product should not be flushed down the toilet or released into the environment. It is recommended to use drug take-back programs or consult with a pharmacist for proper pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Drosperin found in:

A-Z Index: